Effect of non-oral estrogen on risk markers for metabolic syndrome in early surgically menopausal women

Abstract

Transdermal estrogen treatment has a protective effect against the risk factors of metabolic syndrome (homocysteine, ADMA, HDL cholesterol) in surgically menopausal patients who have undergone surgery in the early premenopausal period.